Shengjia Chen

589 total citations
26 papers, 395 citations indexed

About

Shengjia Chen is a scholar working on Molecular Biology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Shengjia Chen has authored 26 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 7 papers in Cancer Research and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Shengjia Chen's work include GDF15 and Related Biomarkers (4 papers), Cancer-related molecular mechanisms research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Shengjia Chen is often cited by papers focused on GDF15 and Related Biomarkers (4 papers), Cancer-related molecular mechanisms research (4 papers) and Lung Cancer Treatments and Mutations (4 papers). Shengjia Chen collaborates with scholars based in China, United States and Hong Kong. Shengjia Chen's co-authors include Xingya Wang, Xiaojian Lin, Chaojie Chen, Jiajun Chen, Peng He, Qian Zhao, Tingting Sang, Ying Wang, Thomas E. Eling and Liu Fang and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and Journal of Agricultural and Food Chemistry.

In The Last Decade

Shengjia Chen

17 papers receiving 392 citations

Peers

Shengjia Chen
Khrystyna Platko Canada
Jae Hyun Byun Canada
Haoyu Tian China
Arturo Simoni‐Nieves Mexico
Lucía Barbier‐Torres United States
Haiyang Li China
Bohao Liu China
Paul Lebeau Canada
Haizhao Yan China
Linghao Wang China
Khrystyna Platko Canada
Shengjia Chen
Citations per year, relative to Shengjia Chen Shengjia Chen (= 1×) peers Khrystyna Platko

Countries citing papers authored by Shengjia Chen

Since Specialization
Citations

This map shows the geographic impact of Shengjia Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengjia Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengjia Chen more than expected).

Fields of papers citing papers by Shengjia Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shengjia Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengjia Chen. The network helps show where Shengjia Chen may publish in the future.

Co-authorship network of co-authors of Shengjia Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Shengjia Chen. A scholar is included among the top collaborators of Shengjia Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shengjia Chen. Shengjia Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Shengjia, et al.. (2026). OMD: optimal transport-guided multimodal disentangled learning for leptomeningeal metastasis diagnosis. Information Fusion. 130. 104121–104121.
2.
Lin, Xiaojian, Dongjie Chen, Shengjia Chen, et al.. (2025). UPLC-Q-TOF/MS-based study on chemical composition, in vivo metabolites, and tissue distribution of ethanol extract of Ganoderma lucidum. Journal of Pharmaceutical and Biomedical Analysis. 263. 116886–116886. 2 indexed citations
3.
Zhang, Chaojie, Shengjia Chen, Çiğdem Özkan, et al.. (2025). MR-Transformer: A Vision Transformer-based Deep Learning Model for Total Knee Replacement Prediction Using MRI. Radiology Artificial Intelligence. 7(5). e240373–e240373.
4.
Campanella, Gabriele, Shengjia Chen, Ruchika Verma, et al.. (2025). A clinical benchmark of public self-supervised pathology foundation models. Nature Communications. 16(1). 3640–3640. 15 indexed citations
5.
6.
Hong, Yaping, Haipeng Xu, Qin Shi, et al.. (2024). Plasma EGFR mutation ctDNA dynamics in patients with advanced EGFR-mutated NSCLC treated with Icotinib: phase 2 multicenter trial result. Scientific Reports. 14(1). 23115–23115. 3 indexed citations
7.
8.
9.
Hong, Yaping, Qian Miao, Yiquan Xu, et al.. (2023). Effects of intrathecal pemetrexed on the survival of patients with leptomeningeal metastasis from lung adenocarcinoma: a propensity score matching analysis. Journal of Neuro-Oncology. 165(2). 301–312. 4 indexed citations
10.
Wang, Ying, Shengjia Chen, Jiajun Chen, et al.. (2023). Characterization and phylogenetic analysis of the complete mitochondrial genome sequence of Photinia serratifolia. Scientific Reports. 13(1). 770–770. 29 indexed citations
11.
Guo, Chang‐Ying, Shengjia Chen, Yongqiang Ye, & Weimin Mao. (2023). A phase II study to evaluate anlotinib plus TQB2450 as adjuvant therapy in patients with esophageal squamous cell carcinoma (ALTER-E005).. Journal of Clinical Oncology. 41(4_suppl). TPS488–TPS488.
12.
13.
14.
Wang, Ying, Jiajun Chen, Tingting Sang, et al.. (2022). NAG-1/GDF15 protects against streptozotocin-induced type 1 diabetes by inhibiting apoptosis, preserving beta-cell function, and suppressing inflammation in pancreatic islets. Molecular and Cellular Endocrinology. 549. 111643–111643. 19 indexed citations
15.
Wang, Ying, Chaojie Chen, Jiajun Chen, et al.. (2022). Overexpression of NAG-1/GDF15 prevents hepatic steatosis through inhibiting oxidative stress-mediated dsDNA release and AIM2 inflammasome activation. Redox Biology. 52. 102322–102322. 86 indexed citations
16.
Chen, Shengjia, et al.. (2022). Genomic characterization of immune checkpoint inhibitor resistance genes and hyperprogression related genes in advanced lung cancer.. Journal of Clinical Oncology. 40(16_suppl). e21042–e21042.
17.
Chen, Jiajun, Peng He, Chaojie Chen, et al.. (2022). NAG-1/GDF15 inhibits diabetic nephropathy via inhibiting AGE/RAGE-mediated inflammation signaling pathways in C57BL/6 mice and HK-2 cells. Life Sciences. 311(Pt A). 121142–121142. 48 indexed citations
18.
Lu, Zihao, et al.. (2021). Cisplatin resistance of NSCLC cells involves upregulation of visfatin through activation of its transcription and stabilization of mRNA. Chemico-Biological Interactions. 351. 109705–109705. 12 indexed citations
19.
Xu, Jiajun, Zhixi Chen, Zheng Fang, et al.. (2021). Long non‑coding RNA OIP5‑AS1 promotes the progression of esophageal cancer by regulating miR‑30a/VOPP1 expression. Oncology Letters. 22(3). 651–651. 10 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Khrystyna Platko Breakdown of academic impact, for papers by Jae Hyun Byun Breakdown of academic impact, for papers by Haoyu Tian Breakdown of academic impact, for papers by Arturo Simoni‐Nieves Breakdown of academic impact, for papers by Lucía Barbier‐Torres Breakdown of academic impact, for papers by Haiyang Li Breakdown of academic impact, for papers by Bohao Liu Breakdown of academic impact, for papers by Paul Lebeau Breakdown of academic impact, for papers by Haizhao Yan Breakdown of academic impact, for papers by Linghao Wang
Rankless by CCL
2026